

24<sup>th</sup> October 2016

## **CANQURA TO BEGIN LIVE TESTING OF G3 FOR AML CANCER**

On 14<sup>th</sup> October 2016, Canqura AB signed an agreement together with our partners at Experia and with the Karolinska Institute in Stockholm to begin the 5 steps of planned tests to establish the effectiveness of QURA100 in a live environment. A summary of these 5 steps was sent to all contacts in June this year.

Iscomed AB, is to fund the first 3 steps and we continue our fund-raising efforts to complete the full testing program during its course. A total of approximately \$190K is required to complete these tests.

To date, lab tests and other indications all point to a successful outcome and professional observations of QURA100 suggest that the results of these live animal tests will show the effectiveness of the compound in the treatment of Leukaemia. Experia anticipates that upon successful completion, further funding for human studies will be secured.

Work begins immediately with ultimate results expected by Q2 if 2017.

Canqura AB is a Moreinx Company

JC/15OCT161